OraSure Technologies, Inc. Stock News

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q4 2024 Results Conference Call February 25, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Casey Woodring - JPMorgan Andrew Cooper - Raymond James Operator Welcome to the...

BETHLEHEM, Pa., Feb. 14, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2024 financial results and certain business developments for 5 p.m. ET on February 25, 2025.

SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics, Inc. (NOWDx), a leader in developing over-the-counter (OTC) and point-of-care (POC) diagnostic tests, filed a claim on Jan. 13 against OraSure Technologies (OraSure), asserting breach of contract, theft of a non-public device, misappropriation of trade secrets, unfair competition, and other violations of state and federal law for damages in fed...

BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. OraSure's presentation is scheduled for Thursday, January 16, 2025 at 9:00 a.m. PT.

BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, January 7th by OraSure Technologies, Inc. (NASDAQ: OSUR), please note that the first sentence of the release (read "OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents.") is incomplete. The corrected release follows:

BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older.

BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.

OraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no long-term debt and $280 million in cash, mitigating downside risks. Post-COVID margins are expected to improve, driving positive cash flow and substantial upside potential, with a projected 70%+ appr...